PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials
出版年份 2012 全文链接
标题
PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials
作者
关键词
-
出版物
Clinical Lipidology
Volume 7, Issue 6, Pages 621-640
出版商
Future Medicine Ltd
发表日期
2012-12-18
DOI
10.2217/clp.12.74
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels
- (2012) Ekaterina Chernogubova et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy
- (2012) Payal Kohli et al. CLINICAL CARDIOLOGY
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
- (2012) Maartje E. Visser et al. EUROPEAN HEART JOURNAL
- An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
- (2012) Liwen Zhang et al. International Journal of Biological Sciences
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
- (2012) David Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9
- (2012) Javier Chaparro-Riggers et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice
- (2012) Elena Fattori et al. JOURNAL OF LIPID RESEARCH
- Calcium-Independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF(A) Domain
- (2012) Yingnan Zhang et al. JOURNAL OF MOLECULAR BIOLOGY
- Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels
- (2012) Clapton S. Dias et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- RETRACTED: Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial
- (2012) Roeland Huijgen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- (2012) James M. McKenney et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Statins for people at low risk of cardiovascular disease – Authors' reply
- (2012) Borislava Mihaylova et al. LANCET
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
- (2012) Evan A Stein et al. LANCET
- LDL Cholesterol: The Lower the Better
- (2012) Seth S. Martin et al. MEDICAL CLINICS OF NORTH AMERICA
- PCSK9 antibody reduces LDL cholesterol
- (2012) Sarah Crunkhorn NATURE REVIEWS DRUG DISCOVERY
- The biology and therapeutic targeting of the proprotein convertases
- (2012) Nabil G. Seidah et al. NATURE REVIEWS DRUG DISCOVERY
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor–independent pathways
- (2012) Jamie Cameron et al. Translational Research
- Institutional, provider, and patient correlates of low-density lipoprotein and non–high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines
- (2011) Salim S. Virani et al. AMERICAN HEART JOURNAL
- Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial
- (2011) Z. Awan et al. CLINICAL CHEMISTRY
- Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture
- (2011) J. Mayne et al. CLINICAL CHEMISTRY
- Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
- (2011) Paola Lo Surdo et al. EMBO REPORTS
- Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification
- (2011) K. Tveten et al. HUMAN MOLECULAR GENETICS
- Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
- (2011) Øystein L. Holla et al. JOURNAL OF LIPID RESEARCH
- PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates
- (2011) Marie W Lindholm et al. MOLECULAR THERAPY
- Pharmacological strategies for lowering LDL cholesterol: statins and beyond
- (2011) Ariel Brautbar et al. Nature Reviews Cardiology
- Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients
- (2010) P. Costet et al. ATHEROSCLEROSIS
- Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study
- (2010) L A Donnelly et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
- (2010) Yan G. Ni et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- In VivoEvidence That Furin from Hepatocytes Inactivates PCSK9
- (2010) Rachid Essalmani et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor
- (2010) Taichi Yamamoto et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
- (2010) Yan G. Ni et al. JOURNAL OF LIPID RESEARCH
- High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
- (2010) Greg Welder et al. JOURNAL OF LIPID RESEARCH
- PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
- (2010) Marianne Benn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
- (2010) Peter Duewell et al. NATURE
- Rational design of cationic lipids for siRNA delivery
- (2010) Sean C Semple et al. NATURE BIOTECHNOLOGY
- A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
- (2010) Nidhi Gupta et al. PLoS One
- Adnectins: engineered target-binding protein therapeutics
- (2010) D. Lipovsek PROTEIN ENGINEERING DESIGN & SELECTION
- Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles
- (2009) Giuseppe Danilo Norata et al. ATHEROSCLEROSIS
- Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
- (2009) Christopher J. Duff et al. BIOCHEMICAL JOURNAL
- Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels
- (2009) Chiang-Ching Huang et al. Circulation-Cardiovascular Genetics
- Healthy Individuals Carrying the PCSK9 p.R46L Variant and Familial Hypercholesterolemia Patients Carrying PCSK9 p.D374Y Exhibit Lower Plasma Concentrations of PCSK9
- (2009) S. E. Humphries et al. CLINICAL CHEMISTRY
- Major Lipids, Apolipoproteins, and Risk of Vascular Disease
- (2009) The Emerging Risk Factors Collaboration* JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Hepatocyte Nuclear Factor 1α Plays a Critical Role inPCSK9Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
- (2009) Hai Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
- (2009) Markey C. McNutt et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation
- (2009) Steve Poirier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
- (2009) Jason S. Troutt et al. JOURNAL OF LIPID RESEARCH
- A new method for measurement of total plasma PCSK9: clinical applications
- (2009) Geneviève Dubuc et al. JOURNAL OF LIPID RESEARCH
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
- (2009) J. C. Y. Chan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Longitudinal Evaluation and Assessment of Cardiovascular Disease in Patients With Homozygous Familial Hypercholesterolemia
- (2008) Daniel M. Kolansky et al. AMERICAN JOURNAL OF CARDIOLOGY
- The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia
- (2008) Jean-Charles Fruchart et al. AMERICAN JOURNAL OF CARDIOLOGY
- Berberine decreases PCSK9 expression in HepG2 cells
- (2008) Jamie Cameron et al. ATHEROSCLEROSIS
- PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
- (2008) LiXin Shan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment
- (2008) G. Lambert et al. CLINICAL CHEMISTRY
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9
- (2008) Sanae Kourimate et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants
- (2008) Matthew J. Bottomley et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels
- (2008) Gaétan Mayer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
- (2008) Yi Luo et al. JOURNAL OF LIPID RESEARCH
- Plasma PCSK9 preferentially reduces liver LDL receptors in mice
- (2008) Aldo Grefhorst et al. JOURNAL OF LIPID RESEARCH
- PCSK9: a convertase that coordinates LDL catabolism
- (2008) Jay D. Horton et al. JOURNAL OF LIPID RESEARCH
- Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
- (2008) Janice Mayne et al. Lipids in Health and Disease
- A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
- (2008) Akin Akinc et al. NATURE BIOTECHNOLOGY
- Molecular basis for LDL receptor recognition by PCSK9
- (2008) H. J. Kwon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor
- (2008) D.-W. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
- (2008) M. Frank-Kamenetsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa
- (2007) Vivienne M. Homer et al. ATHEROSCLEROSIS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started